Zhang, Shijia http://orcid.org/0000-0002-7423-9255
Kulkarni, Amit A.
Xu, Beibei
Chu, Haitao
Kourelis, Taxiarchis
Go, Ronald S. http://orcid.org/0000-0002-8284-3495
Wang, Michael L. http://orcid.org/0000-0001-9748-5486
Bachanova, Veronika http://orcid.org/0000-0002-9325-432X
Wang, Yucai http://orcid.org/0000-0002-1576-8341
Article History
Received: 2 October 2019
Revised: 11 February 2020
Accepted: 18 February 2020
First Online: 6 March 2020
Conflict of interest
: Dr. Michael Wang made the following disclosures: research grants, consulting/advisory board, and honoraria—Janssen and Acerta Pharma; research grants and consulting/advisory board—Pharmacyclics, AstraZeneca, Celgene, Juno Therapeutics, Loxo Oncology, Kite Pharma, and BioInvent; research grants—BeiGene, VelosBio, and Aviara; consulting/advisory board—Pulse Biosciences and Guidepoint Global; consulting/advisory board and stock—MoreHealth; honoraria—OMI, Physicians Education Resources, and Oncology News, outside the submitted work. Dr. Veronika Bachanova reported non-financial support from ArticulateScience, grants from Novartis, grants from GT Biopharma, personal fees from Seattle Genetics, Kite Pharma, and Zymogen, outside the submitted work. No other disclosures were reported.